Among 14 analysts covering Qiagen (NASDAQ:QGEN), 5 have Buy rating, 0 Sell and 9 Hold. Therefore 36% are positive. Qiagen had 24 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was initiated by Stifel Nicolaus on Thursday, November 12 with “Hold”. Bank of America upgraded QIAGEN N.V. (NASDAQ:QGEN) on Thursday, November 3 to “Neutral” rating. The company was initiated on Tuesday, September 15 by Morgan Stanley. Piper Jaffray maintained QIAGEN N.V. (NASDAQ:QGEN) on Friday, July 28 with “Hold” rating. The firm earned “Hold” rating on Monday, August 14 by Cowen & Co. Independent Research upgraded the stock to “Hold” rating in Tuesday, August 1 report. The stock has “Overweight” rating by Barclays Capital on Thursday, July 30. On Wednesday, September 13 the stock rating was maintained by Jefferies with “Hold”. Evercore initiated the shares of QGEN in report on Wednesday, January 3 with “Buy” rating. The rating was maintained by Cowen & Co on Tuesday, January 2 with “Hold”. See QIAGEN N.V. (NASDAQ:QGEN) latest ratings:
03/01/2018 Broker: Evercore Rating: Buy New Target: $35.0 Initiate
02/01/2018 Broker: Cowen & Co Rating: Hold New Target: $33.0 Maintain
20/12/2017 Broker: Cowen & Co Rating: Hold New Target: $34.0 Maintain
27/09/2017 Broker: Cowen & Co Rating: Hold New Target: $33.0 Maintain
13/09/2017 Broker: Jefferies Rating: Hold New Target: $33.0 Maintain
14/08/2017 Broker: Cowen & Co Rating: Hold New Target: $33.0000 Maintain
01/08/2017 Broker: Independent Research Old Rating: Sell New Rating: Hold Upgrade
28/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $29.0000 Maintain
17/07/2017 Broker: Barclays Capital Rating: Buy New Target: $37.0000
Umb Bank N A decreased Jpmorgan Chase & Co (JPM) stake by 12.34% reported in 2017Q3 SEC filing. Umb Bank N A sold 62,436 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.04%. The Umb Bank N A holds 443,542 shares with $42.36 million value, down from 505,978 last quarter. Jpmorgan Chase & Co now has $378.29 billion valuation. The stock increased 1.43% or $1.54 during the last trading session, reaching $109.04. About 12.95 million shares traded or 1.66% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since January 5, 2017 and is uptrending. It has outperformed by 17.04% the S&P500.
Among 32 analysts covering JPMorgan Chase & Co (NYSE:JPM), 18 have Buy rating, 2 Sell and 12 Hold. Therefore 56% are positive. JPMorgan Chase & Co has $132.0 highest and $52 lowest target. $92.42’s average target is -15.24% below currents $109.04 stock price. JPMorgan Chase & Co had 95 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Neutral” rating given on Friday, October 13 by Nomura. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Hold” rating given on Wednesday, October 11 by Keefe Bruyette & Woods. Keefe Bruyette & Woods maintained JPMorgan Chase & Co. (NYSE:JPM) on Tuesday, October 3 with “Hold” rating. Buckingham Research downgraded JPMorgan Chase & Co. (NYSE:JPM) rating on Monday, October 17. Buckingham Research has “Neutral” rating and $74 target. Vetr downgraded the stock to “Strong-Buy” rating in Friday, August 28 report. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Neutral” rating given on Friday, January 15 by UBS. The rating was maintained by Jefferies with “Buy” on Friday, July 7. Credit Suisse maintained JPMorgan Chase & Co. (NYSE:JPM) on Monday, July 17 with “Outperform” rating. The stock has “Neutral” rating by Macquarie Research on Friday, September 9. As per Wednesday, April 26, the company rating was upgraded by Guggenheim.
Umb Bank N A increased V F Corp (NYSE:VFC) stake by 116,767 shares to 608,618 valued at $38.69 million in 2017Q3. It also upped Vanguard Reit Vipers Etf (VNQ) stake by 7,488 shares and now owns 353,581 shares. First Trust Mlp And Energy I (FEI) was raised too.
Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on January, 12 before the open. They expect $1.70 EPS, down 0.58% or $0.01 from last year’s $1.71 per share. JPM’s profit will be $5.90 billion for 16.04 P/E if the $1.70 EPS becomes a reality. After $1.76 actual EPS reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts -3.41% negative EPS growth.
Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.28, from 1.19 in 2017Q2. It is negative, as 65 investors sold JPM shares while 767 reduced holdings. 125 funds opened positions while 635 raised stakes. 2.50 billion shares or 7.05% less from 2.69 billion shares in 2017Q2 were reported. Lord Abbett & Limited Company accumulated 1.2% or 4.30 million shares. Bessemer Group reported 0.8% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Moreover, Culbertson A N And Inc has 3.56% invested in JPMorgan Chase & Co. (NYSE:JPM). Ferguson Wellman Management owns 1.57% invested in JPMorgan Chase & Co. (NYSE:JPM) for 455,312 shares. Oklahoma-based George Kaiser Family Foundation has invested 1.53% in JPMorgan Chase & Co. (NYSE:JPM). Maryland Capital Management invested 0.47% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Macnealy Hoover Investment reported 21,523 shares stake. Hitchwood Cap Limited Partnership reported 1.10M shares or 4.49% of all its holdings. Edge Wealth Management Ltd Liability holds 92,938 shares or 2.68% of its portfolio. First Bancorp Of Omaha owns 328,158 shares for 1.92% of their portfolio. Coe Capital Mgmt holds 2.69% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM) for 27,101 shares. Acg Wealth, Georgia-based fund reported 71,702 shares. Deutsche Financial Bank Ag invested 0.74% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Roof Eidam And Maycock Adv invested 0.26% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). 63,347 are held by Novare Ltd Company.
Since August 21, 2017, it had 0 insider purchases, and 2 selling transactions for $1.12 million activity. $214,019 worth of stock was sold by Friedman Stacey on Wednesday, October 25.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company has market cap of $7.30 billion. It offers sample technologies for plasmid deoxyribonucleic acid purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It has a 84.4 P/E ratio. The firm provides Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.
The stock increased 0.97% or $0.31 during the last trading session, reaching $32.24. About 984,815 shares traded. QIAGEN N.V. (NASDAQ:QGEN) has risen 54.62% since January 5, 2017 and is uptrending. It has outperformed by 37.92% the S&P500.